- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
- Interventions
- Placebo, Memantine Hydrochloride, OROS-Methylphenidate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- ADHD
- Interventions
- ADHD Therapy, Control Therapy
- Device
- Lead sponsor
- Lumos Labs, Inc.
- Industry
- Eligibility
- 22 Years to 55 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Garden Grove, California • Sacramento, California + 10 more
- Conditions
- ADHD Specifically With Executive Function Impairment
- Interventions
- SPD489, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 39
- States / cities
- Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 34 more
- Conditions
- ADHD, Smoking
- Interventions
- Osmotic-Release Methylphenidate, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 6
- States / cities
- Cambridge, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
- Interventions
- Centanafadine SR, Placebo
- Drug · Other
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline, Placebo
- Drug · Other
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 48 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Lisdexamfetamine
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- IR Viloxazine, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 4
- States / cities
- Bradenton, Florida • Libertyville, Illinois • Owensboro, Kentucky + 1 more
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Atomoxetine, Buspirone
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Diego, California • Orlando, Florida + 5 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- SPD465, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 19 Years to 25 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- ABT-089, Placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 23
- States / cities
- Mesa, Arizona • Lafayette, California • Oceanside, California + 20 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- TC-5619-238 5mg, TC-5619-238 25mg, Placebo
- Drug
- Lead sponsor
- Targacept Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • National City, California • Colorado Springs, Colorado + 9 more
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Cognitive behavioral therapy, Drug therapy
- Behavioral · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cocaine-Related Disorders, Substance-Related Disorders
- Interventions
- Methylphenidate
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 21 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1999
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Adult Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Daytrana (methylphenidate patch)
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Attention-Deficit/Hyperactivity Disorder, ADHD
- Interventions
- ABT-894, atomoxetine, placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 22
- States / cities
- San Francisco, California • Wildomar, California • Orlando, Florida + 19 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Interventions
- Vyvanse (lisdexamfetamine dimesylate), NRP104
- Drug
- Lead sponsor
- New River Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 45
- States / cities
- Little Rock, Arkansas • El Centro, California • Irvine, California + 40 more
- Conditions
- Adult Attention-Deficit Hyperactivity Disorder
- Interventions
- Guanfacine Hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Rochester Center for Behavioral Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Rochester Hills, Michigan
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Experimental: methylphenidate treatment
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 35
- States / cities
- Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more
- Conditions
- Smoking, Withdrawal Nicotine, ADHD
- Interventions
- Cigarette smoking, Abstinence
- Behavioral
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Santa Ana, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Meta Quest 3 VR Headset with noise cancelling headphones
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Baton Rouge, Louisiana • New Brunswick, New Jersey
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- PRC-063, lisdexamfetamine dimesylate, Placebo
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- ADHD
- Interventions
- PRC-063 oral capsules, Placebo oral capsules
- Drug
- Lead sponsor
- Purdue Pharma, Canada
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 8
- States / cities
- Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more